MPD: Phenotype measures mapped to MA:0000168, brain

Phenotype measures directly associated with ontology term
MA:0000168 'brain'

This list only includes measures mapped to MA:0000168 directly. Measures mapped to its ontology descendants are not included. Alternatively, you can show measures mapped to MA:0000168 AND its descendants.

MA:0000188 corpus callosum
MA:0000191 hippocampus
MA:0000198 cerebellum
MA:0000817 brain subventricular zone
MA:0000941 temporal cortex
MA:0000946 dentate gyrus granule cell layer
MA:0002723 hippocampal commissure

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Bopp1:4	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in brain relative to all organs tested [%] luciferase_brain 36404	inbred	28	both	8-12wks	N=2	2010

Brich1:1	Brich1	metabolite quantification	(none)	tau phosphorylation level [score] level 12801	QTL population		f	3wks	N=51	2003

Brinkmeyer1:33	Brinkmeyer1	RNA expression profiling	Theiler's murine encephalomyelitis virus	TMEV transcript abundance (normalized), post infection TMEV 64433 day 7 day 28	CC	4	both	4wks	N=1	2017

Chesler3:91	Chesler3	organ weights	(none)	brain weight [g] brain_wt 43591	CC pre w/par	181	both	7-15wks	N=1	2011

Crabbe2:1	Crabbe2	drug and metabolite quantification	diazepam	brain diazepam and metabolite concentration, 30 min post-injection [ng/g] brain_DZ 15501 8 mg/kg 16 mg/kg	inbred	15	m	6-7wks	N=8	1998

Crabbe2:3	Crabbe2	drug and metabolite quantification	diazepam	brain diazepam and metabolite concentration, <5 min post-injection, after rotarod [ng/g] brain_DZ20 15503 trial block1 trial block2	inbred	15	m	6-7wks	N=13	1998

Crusio1:45	Crusio1	organ weights	(none)	brain weight [g] brain_wt 62045	BXD w/par	55	both	12-16wks	N=8	2018

Crusio1:46	Crusio1	organ weights	(none)	brain weight as percentage of total body weight [%] brain_wt_pct 62046	BXD w/par	55	both	12-16wks	N=8	2018

Davidson1:1	Davidson1	health assessment	(none)	0=exencephaly, 1=normal [score] Exencephaly 19201	QTL population		both	embryo	N=94	2007

Davidson1:2	Davidson1	health assessment	(none)	1=exencephaly, 0=normal [score] Exen2 19202	QTL population		both	embryo	N=94	2007

Frankel1:1	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for minimal clonic seizure, frontal stimulation (at BH) [mA] E_MC_BH_FS 5601	inbred	4	m	6-11wks	N=35	2000

Frankel1:2	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀), transcorneal stimulation (at BH) [mA] E_MC_BH_TC 5602	inbred	16	both	6-11wks	N=33	2000

Frankel1:3	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀), transcorneal stimulation (at SL) [mA] E_MC_SL_TC 5603	inbred	8	both	6-11wks	N=29	2000

Frankel1:4	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, frontal stimulation (at BH) [mA] E_MT_BH_FS 5604	inbred	4	m	6-11wks	N=44	2000

Frankel1:5	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, transcorneal stimulation (at BH) [mA] E_MT_BH_TC 5605	inbred	16	both	6-11wks	N=38	2000

Frankel1:6	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, transcorneal stimulation (at SL) [mA] E_MT_SL_TC 5606	inbred	8	both	6-11wks	N=29	2000

Frankel1:7	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, frontal stimulation (at BH) [mA] E_PS_BH_FS 5607	inbred	4	m	6-11wks	N=41	2000

Frankel1:8	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, transcorneal stimulation (at BH) [mA] E_PS_BH_TC 5608	inbred	14	both	6-11wks	N=41	2000

Frankel1:9	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, transcorneal stimulation (at SL) [mA] E_PS_SL_TC 5609	inbred	7	both	6-11wks	N=39	2000

Frankel1:10	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against minimal clonic seizures (CC₉₇), transcorneal stimulation (at BH) [mg/kg] L_MC_BH_TC 5610	inbred	3	m	6-11wks	N=63	2000

Frankel1:12	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against minimal clonic seizures (CC₉₇), transcorneal stimulation (at SL) [mg/kg] L_MC_SL_TC 5612	inbred	3	m	6-11wks	N=51	2000

Frankel1:13	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against maximal tonic hindlimb extension seizure (CC₉₇), transcorneal stimulation (at BH) [mg/kg] L_MT_BH_TC 5613	inbred	3	m	6-11wks	N=52	2000

Frankel1:14	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against maximal tonic hindlimb extension seizure (CC₉₇), transcorneal stimulation (at SL) [mg/kg] L_MT_SL_TC 5614	inbred	3	m	6-11wks	N=45	2000

Gould1:8	Gould1	drug and metabolite quantification	lithium	brain lithium concentration [mmol/L] brain_lithium 37408 lithium dose [mg/kg]: 200 300 400	inbred	11	m	7-8wks	N=8	2011

Graham1:29	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD4+ in brain, post infection [%] CD4_brain 63329 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:37	Graham1	immune cell quantification	West Nile virus	percentage of CD4+ T cells that are Foxp3+ in the brain, post infection [%] Treg_brain 63337 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:45	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD8+ in brain, post infection [%] CD8_brain 63345 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:53	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are NS4b+ in brain, post infection [%] NS4b_brain 63353 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:65	Graham1	RNA expression profiling	West Nile virus	virus in brain, fold change compared to matched control, post infection WNV_brain 63365 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:76	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in brain, fold change compared to matched control, post infection Ifnb1_brain 63376 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:87	Graham1	RNA expression profiling	West Nile virus	Ifit1 gene expression in brain, fold change compared to matched control, post infection Ifit1_brain 63387 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Jaxpheno2:1	Jaxpheno2	organ weights	(none)	brain weight [g] brain 22701 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno2:3	Jaxpheno2	organ weights	(none)	brain weight as percentage of body weight [%] pct_brain 22703 age 8wks age 16wks	inbred	11	both		N=8	2006

Marchuk1:1	Marchuk1	histopathology	(none)	infarct volume following surgically-induced focal cerebral ischemia [mm³] infarct_vol 45001	inbred	16	both	11-13wks	N=4	2009

Molenhuis1:8	Molenhuis1	organ weights	(none)	brain weight [g] brain_wt 110075	CC	52	m	7-20wks	N=5	2018

Reed2:31	Reed2	organ weights	(none)	brain weight [g] brain_wt 53131	B6.129 and 129.B6 consomic w/par	9	both	26wks	N=17	2015

Richfield1:22	Richfield1	neurotransmitter quantification	(none)	dopamine (DA), ng per mg total protein [ratio] DA 14522	inbred	15	m	7-9wks	N=10	2003

Richfield1:23	Richfield1	neurotransmitter quantification	(none)	3,4-dihydroxyphenylacetic acid (DOPAC), ng per mg total protein [ratio] DOPAC 14523	inbred	15	m	7-9wks	N=10	2003

Richfield1:24	Richfield1	neurotransmitter quantification	(none)	4-hydroxy-3-methoxyphenylacetic acid (HVA), ng per mg total protein [ratio] HVA 14524	inbred	15	m	7-9wks	N=10	2003

Richfield1:25	Richfield1	neurotransmitter quantification	(none)	serotonin (5HT), ng per mg total protein [ratio] 5HT 14525	inbred	15	m	7-9wks	N=10	2003

Richfield1:26	Richfield1	neurotransmitter quantification	(none)	dopamine turnover ([DOPAC]/[DA]) [ratio] DA_turnover1 14526	inbred	15	m	7-9wks	N=10	2003

Richfield1:27	Richfield1	neurotransmitter quantification	(none)	dopamine turnover ([DOPAC] + [HVA]/[DA]) [ratio] DA_turnover2 14527	inbred	15	m	7-9wks	N=10	2003

Schauwecker1:1	Schauwecker1	health assessment	pilocarpine	pilocarpine dose required to induce status epilepticus, mg/kg body weight [mg/kg] ED100 47701	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:2	Schauwecker1	health assessment	pilocarpine	latency to onset of stage 4 status epilepticus seizures [min] latency 47702	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:3	Schauwecker1	health assessment	pilocarpine	duration of stage 4 status epilepticus seizures [min] duration 47703	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:4	Schauwecker1	health assessment	pilocarpine	status epilepticus seizure mortality (0=died; 1=survived) [designation] survival 47704	inbred	11	m	8-10wks	N=18	2012

Tsaih1:2	Tsaih1	organ weights	(none)	mean of the brain weight in each line mean_brain 18102	QTL population		both		N=106	2005

Wahlsten1:4	Wahlsten1	organ weights	(none)	brain weight, after fixation and trimming [g] brain_wt 10804 weight as percent of body weight	inbred	21	both	12wks	N=10	2003

Wiltshire3:1	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex ACTH, relative fluorescence intensity ACTH 38101 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:4	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex APOD, relative fluorescence intensity APOD 38104 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:7	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BAG1, relative fluorescence intensity BAG1 38107 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:10	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BDNF, relative fluorescence intensity BDNF 38110 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:13	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex CREB1 (CREB), relative fluorescence intensity CREB1 38113 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:16	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FOS (c-fos), relative fluorescence intensity FOS 38116 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:19	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:22	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAD1 (GAD67), relative fluorescence intensity GAD1 38122 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:25	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAL, relative fluorescence intensity GAL 38125 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:28	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:31	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GHRL, relative fluorescence intensity GHRL 38131 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:34	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:37	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GLO1, relative fluorescence intensity GLO1 38137 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:40	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GNB1, relative fluorescence intensity GNB1 38140 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:43	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GRIN1 (NMDA1), relative fluorescence intensity GRIN1 38143 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:46	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSK3B, relative fluorescence intensity GSK3B 38146 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:49	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSR, relative fluorescence intensity GSR 38149 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:52	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex HDAC5, relative fluorescence intensity HDAC5 38152 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:55	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NGF, relative fluorescence intensity NGF 38155 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:58	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NPY, relative fluorescence intensity NPY 38158 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:61	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex P2RX7 (P2X7), relative fluorescence intensity P2RX7 38161 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:64	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PAQR8, relative fluorescence intensity PAQR8 38164 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:67	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PPP1R1B, relative fluorescence intensity PPP1R1B 38167 control fluoxetine	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:70	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:73	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex S100B, relative fluorescence intensity S100B 38173 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:76	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SCG5 (SGNE), relative fluorescence intensity SCG5 38176 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:79	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A2 (NET), relative fluorescence intensity SLC6A2 38179 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:82	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:85	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SST, relative fluorescence intensity SST 38185 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:88	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex TNF (TNFa), relative fluorescence intensity TNF 38188 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:91	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex VEGFA (VEGF), relative fluorescence intensity VEGFA 38191 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Filter Table Results